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Background: The purpose of this study is to evaluate the predictive significance of preoperative serum level of
cytokeratin 19 fragments (Cyfra21-1) and squamous cell carcinoma antigen (SCC-Ag) after complete resection in
patients with stage II esophageal squamous cell carcinoma (ESCC).
Methods: Between 1995 and 2006, a total of 379 patients in stage II ESCC who underwent complete resection
were consecutively recruited. Statistical analyses were applied to test the associations between preoperative serum
titers of Cyfra21-1 and SCC-Ag, clinicopathological factors and prognoses.
Results: Preoperative high and normal serum level of Cyfra21-1 and SCC-Ag were found in 47.8%, 52.2% and 72.8%,
27.2%, respectively. The 1-, 3-, 5-year overall survival rate for the entire cohort of patients was 95%, 78%, and 56%,
respectively. Median overall survival (OS) was 45.3 months longer in patients with low preoperative serum level of
Cyfra21-1 (91.9 months) than those with high preoperative serum level of Cyfra21-1 (46.6 months) (P < 0.001).
Median OS among patients with SCC-Ag-low level was also longer than those with SCC-Ag-high level (89.7 vs.
63.7 months, P < 0.001), especially for those with stage IIB (P < 0.001). After multivariate analysis, along with pTNM
stage, preoperative serum level of Cyfra21-1 and SCC-Ag were independently and significantly predictive factors
(P < 0.001, P < 0.001). Furthermore, the five-year survival rate in double-low subset, either-low subset and
double-high subset was 100%, 83% and 27%, respectively (P < 0.001).
Conclusions: The preoperative serum level of Cyfra21-1 and SCC-Ag are independently significant predictors which
negatively affected the survivals of patients with stage II ESCC.
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Esophageal cancer is one of the least studied and deadli-
est cancers worldwide and the fourth most frequent
cause of cancer-related deaths in China [1-3]. More than
90 percent of esophageal cancers are squamous cell car-
cinoma in China [3,4]. During the past four decades,
important changes have occurred in the therapeutic
patterns associated with this disease, such as surgery* Correspondence: mr.caoxun@gmail.com
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reproduction in any medium, provided the orcombined with chemotherapy and/or radiotherapy. Re-
cent advances in diagnosis, staging and treatment of this
neoplastic condition have led to promising and signifi-
cant improvements in survival. Clinically, approximately
38-60% of patients present with stage II disease and the
five-year survival ranging from 20% to 50% [5-8].
Additionally, to the best of our knowledge, despite ha-
ving the same stage disease, most patients have different
survival. Therefore, future studies should focus on the
use of molecular biomarkers to predict patient survival
and to select the patients who will benefit from specific
treatment, including adjuvant chemotherapy.
Tumor-related proteins could secrete into the periph-
eral circulation of patients with cancer and may be. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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makers are non-invasive diagnostic tools for indentifying
cancer, and are commonly used for the screening for
cancer and as an indicator of treatment efficacy. Al-
though cytokeratin 19 fragments (Cyfra21-1) and squa-
mous cell carcinoma antigen (SCC-Ag) have been two of
the most commonly used in the diagnosis of a variety of
malignant tumor to date [9-14] the combination of them
to predict the clinical outcomes of esophageal squamous
cell carcinoma (ESCC) have not yet been well elucidated
and established.
In the present study, we herein evaluated the associa-
tions between Cyfra21-1 level,
SCC-Ag level and clinicopathological parameters in a
large cohort of ESCC patients with stage II. Further-
more, we analyzed the prognostic significance of pre-
operative serum level of Cyfra21-1 and SCC-Ag in these
cases.Methods
Ethics Statement
This study was approved by the medical ethics commit-
tee of Cancer Center at Sun Yat-Sen University.Patients
379 patients who underwent curative-intent surgery and
with histologically proven stage II ESCC at Cancer Center,
Sun Yat-Sen University between 1995 and 2006 were
retrospective recruited. The cases exclude from the
current study fulfilled the following criteria: (1) patients
who had received preoperative treatment (chemotherapy
and/or radiotherapy); (2) patients who presented with syn-
chronous primary tumors and/or have previous malignant
disease; (3) patients with a noncurative resection (R1); (4)
patients who died of postoperative complications.
Preoperative evaluation included complete history and
a physical examination, complete blood cell count,
serum biochemistry, chest X-ray, esophageal barium
meal, computed tomography scan of the chest and abdo-
men, endoscopy and an ultrasound scan of abdomen.
The serum level of Cyfra21-1 and SCC-Ag were
examined as a part of the routine preoperative
evaluation within 1 week prior to surgery. According to
the manufacturer (MODULAR ELECSYS E170, Roche,
Mannheim, Germany; ARCHITECT SYSTEM i1000,
Abbott, Tokyo, Japan), the normal upper limit was
3.30 ng/ml for Cyfra21-1 and 1.5 μg/L for SCC-Ag.
According to normal upper limit of the tumor markers,
the patients were divided into low and high subsets. The
Cyfra21-1 and SCC-Ag levels were measured by a radio-
immunoassay (RIA) in the clinical laboratory in our
hospital. Stage was recorded based on American Joint
Committee on Caner (2010) [15].Adjuvant chemotherapy was performed in patients
with stage IIB disease if the patients could tolerate add-
itional treatment after curative-intent surgery, or unless
the patients refused adjuvant chemotherapy. 206 patients
with stage IIB received systemic chemotherapy (cis-
platin-based combinations).
After completion of primary treatment, patients were
followed up every 4–6 months in the first 3 years and
every 12 months thereafter. The survival status was veri-
fied again using the best available methods in May 2010,
including verifying the clinical attendance records and
with direct telecommunication with the patient or their
family.
Statistical Analysis
The statistical analyses were performed using the SPSS
13.0 software package (SPSS, Inc., Chicago, IL). Overall
survival (OS) was defined as the time from the date of
surgery to the date of death or final clinical follow-up.
The correlations between preoperative serum level of
Cyfra21-1 and SCC-Ag and clinicopathological charac-
teristics were assessed using the χ2 test. Multivariate Cox
regression analysis was performed for all parameters that
were found to be significant by the univariate analysis.
Actuarial survival rates were plotted against time using
the Kaplan-Meier method, and log-rank testing was used
to compare the differences between the curves. P < 0.05
was considered statistically significant.
Results
Patient and Disease Characteristics
The median age of the patients was 60 years (range, 31
to 80 years), and 221 (58.3%) cases were men. Of 379
stage II ESCC patients, 253 (66.8%) received a left thora-
cotomy and 126 (33.2%) underwent an Ivor-Lewis/
Three-field technique. The distribution pTNM stages
was 127 stage IIA patients (33.5%), 252 stage IIB patients
(66.5%). The patient and disease characteristics from all
379 patients with stage II ESCC are shown in Table 1.
All further statistical analyses were performed on this
population.
The Preoperative Serum Level of Cyfra21-1 and SCC-Ag
and Their Correlations With Clinicopathological
Characteristics
The preoperative serum levels of Cyfra21-1 and SCC-Ag
were considered to be elevated as high when they
exceeded 3.30 ng/ml and 1.5 μg/L, respectively. In the
whole cohort, high and low serum level of Cyfra21-1
were in 181/379 (47.8%) and 198/379 (52.2%), respec-
tively (Table 1). The preoperative SCC-Ag level was ele-
vated in 72.8% (n= 276) of all patients with stage II
ESCC (Table 1). Further analyses demonstrated that pre-
operative serum levels of SCC-Ag correlated closely with
Table 1 Characteristics of the ESCC patients
Characteristics No. of patients (%)
(N=379)
Age, years†
≤ 60 128 (33.8%)





Left thoracotomy 253 (66.8%)






Grade 1 80 (21.1%)
Grade 2 250 (65.9%)









Stage IIA 127 (33.5%)
Stage IIB 252 (66.5%)
Cyfra21-1 level
Low (≤3.30 ng/ml) 198 (52.2%)
High (>3.30 ng/ml) 181 (47.8%)
SCC-Ag level
Low (≤1.5 μg/L) 103 (27.2%)
High (>1.5 μg/L) 276 (72.8%)
Abbreviation: T, tumor; N, node; TNM, tumor-node-metastasis.
† Median age; {Thoracic-abdominal-cervical incision.
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no correlations were found between preoperative serum
level of Cyfra21-1 and clinicopathological variables
(P > 0.05, Table 2).
The Relationships Between Preoperative Serum Level of
Cyfra21-1 and SCC-Ag, Clinicopathological Characteristics
and ESCC Patient Survival
The median observation period was 52 months (range,
1.9 to 111.3 months), with 201 alive and 178 cancer-related deaths at the last clinical follow-up. The median
and mean OS were 70.9 and 69.6 months, respectively.
The 1-, 3-, 5-year overall survival rate for the entire co-
hort of patients was 95%, 78%, and 56%, respectively
(Figure 1A).
In the Kaplan-Meier analysis, the preoperative serum
level of Cyfra21-1 and SCC-Ag were closely associated
with OS. For the whole cohort, median OS was
45.3 months longer in patient with low preoperative
serum level of Cyfra21-1 (91.9 months) than those with
high preoperative serum level of Cyfra21-1 (46.6 months)
(P < 0.001, Table 3, Figure 1B). Median OS among
patients with SCC-Ag-low level was also longer than
those with SCC-Ag-high level (89.7 vs. 63.7 months,
P < 0.001, Table 3, Figure 1C). Because the preoperative
serum level of Cyfra21-1 and SCC-Ag was found to be
significantly predictive factors for OS, we have further
examined the relationship between preoperative serum
level of Cyfra21-1 and SCC-Ag and survival based upon
patient’s pTNM stage. This analysis showed that the pre-
operative serum level of Cyfra21-1 could distinguish OS
when stratified by stage IIA and stage IIB (P < 0.001,
P < 0.001, Table 3). On the other hand, in patients with
stage IIB ESCC, the 5-year survival rate in SCC-Ag low
group was significantly better (78%) than those of
patients in SCC-Ag high group (45%) (P < 0.001, Table 3).
However, no significant difference was observed in the
5-year survival rate in the patients with stage IIA disease
between the patients with low SCC-Ag serum level and
those with high SCC-Ag serum level (86% vs. 72%,
P= 0.069, Table 3). The 5-year survival rate in double-
low subset, either-low subset and double-high subset
was 100%, 83% and 27%, respectively (P < 0.001,
Figure 1D).
Several clinical and pathological factors were found to
be associated with stage II ESCC patient survival on
both univariate and multivariate analyses (Table 4). On
multivariate analysis, stage IIB (HR, 2.191; P < 0.001),
Cyfra21-1 > 3.30 ng/ml (HR, 7.149; P < 0.001), and SCC-
Ag > 1.5 μg/L (HR, 2.926; P < 0.001) negatively affects
survival of surgically resected stage II ESCC patients.
Discussion
A complete surgical resection is considered to be the
first line treatment for individuals with localized ESCC
[3,16,17]. However, to the best of our knowledge, sub-
stantial differences in survival were observed for the
same TNM stage patients. After complete surgical re-
moval of the tumor, the five-year survival rate is 30 to
40 percent for stage IIA disease, and 10 to 30 percent
for stage IIB disease [5-8]. Those phenomena indicate
that stage II patients who undergo surgery form a het-
erogeneous group in which the disease progression and
survival rate can vary considerately. Thus, there is a
Table 2 The associations between Cyfra21-1 level, SCC-Ag level and the clinicopathological characteristics
No. of patients Cyfra21-1 level SCC-Ag level
Characteristics (%) (N=379) Low High P value* Low High P value*
Tumor location 0.312 0.136
Upper 20 (05.3%) 12 (60.0%) 8 (40.0%) 9 (45.0%) 11 (55.0%)
Middle 260 (68.6%) 129 (49.6%) 131 (50.4%) 71 (27.3%) 189 (72.7%)
Lower 99 (26.1%) 57 (57.6%) 42 (42.4%) 23 (23.2%) 76 (76.8%)
Tumor grade 0.191 0.771
Grade 1 80 (21.1%) 49 (61.2%) 31 (38.8%) 24 (30.0%) 56 (70.0%)
Grade 2 250 (65.9%) 125 (50.0%) 125 (50.0%) 67 (26.8%) 183 (73.2%)
Grade 3 49 (13.0%) 24 (49.0%) 25 (51.0%) 12 (24.5%) 37 (75.5%)
pT status 0.899 0.594
pT1 39 (10.3%) 20 (51.3%) 19 (48.7%) 12 (30.8%) 27 (69.2%)
pT2/3 213 (56.2%) 178 (52.4%) 162 (47.6%) 91 (26.8%) 249 (73.2%)
pN status 0.059 0.005
pN0 127 (33.5%) 75 (59.1%) 52 (40.9%) 46 (36.2%) 81 (63.8%)
pN1 252 (66.5%) 123 (48.8%) 129 (51.2%) 57 (22.6%) 195 (77.4%)
pTNM stage 0.059 0.005
Stage IIA 127 (33.5%) 75 (59.1%) 52 (40.9%) 46 (36.2%) 81 (63.8%)
Stage IIB 252 (66.5%) 123 (48.8%) 129 (51.2%) 57 (22.6%) 195 (77.4%)
Abbreviation: pT, pathological tumor; pN, pathological node; pTNM stage, pathological tumor-node-metastasis stage.
* χ2 test.
Cao et al. Journal of Translational Medicine 2012, 10:197 Page 4 of 7
http://www.translational-medicine.com/content/10/1/197significant need for early identification of patients who
are at increased risk of disease progression after their
primary treatment. A blood-based biomarker is attract-
ive filter because blood is easily accessible and measure-
ments may be repeated over time [18-20].
Several previous studies have revealed that the signifi-
cance of Cyfra21-1 and SCC-Ag level for cancer screen-
ing [21-23]. However, the predictive analysis of Cyfra21-
1 and SCC-Ag level in ESCC, especially in stage II
ESCC, has not been well elucidated and studied. Based
on unique etiology, patient characteristics, uniform
treatment modalities and long term follow-up, the
current study is the first to systematically evaluate the
prognostic value of preoperative serum level of Cyfra21-
1 and SCC-Ag in ESCC. Our findings indicate that pre-
operative Cyfra21-1 and SCC-Ag level significantly asso-
ciated with survival in patients with stage II ESCC.
Cyfra21-1 is a member of the keratin family. It is a
protein that in humans is encoded by the KRT19 gene
[24,25]. Its expression can be observed in many normal
tissues, and it is overexpressed in lung cancer, colorectal
cancer and breast cancer [26-29]. SCC-Ag is a sub-
fraction of the tumor antigen TA-4, a 48 kDa glycopro-
tein first isolated by Kato and Torigoe [30]. SCC-Ag is
released and often elevated in patients who have squa-
mous cell carcinomas. SCC-Ag has become a promising
aid for the management of squamous cell carcinoma in a
variety of sites, such as cervical cancer, head and neckcancer and esophageal cancer. The previous studied have
indicated that Cyfra21-1 and SCC-Ag are sensitive
tumors marker in malignant disease, particularly in
squamous cell type [19,31,32]. In the present study, our
results firstly showed a significant correlation between
the preoperative serum level of SCC-Ag and clinico-
pathological factors (pN status, P= 0.005; pTNM stage,
P= 0.005). This finding corresponds with the studies
from France and Poland [19,21]. However, we failed to
reveal any correlation between the preoperative serum
level of Cyfra21-1 and patient disease characteristics. In
contrast, Moro et al. and Hanagirl et al. reported that
preoperative Cyfra21-1 was associated with tumor stage
in non small cell lung cancer [21,33]. We believe this re-
sult can be explained by three particular factors. Firstly,
various cutoff points might lead to various results. Sec-
ondly, the heterogeneity of tumors might result in the
discrepancies in the findings between the previous litera-
tures and our study. In addition, cohort-specific differ-
ences such as ethnicity and epidemiology might also
explain the observed phenomena. However, this conclu-
sion merits additional research.
To date, the use of serum markers has not been
accepted in assessing prognosis or assigning treatment
after complete resection for ESCC. The prognostic
values of Cyfra21-1 and SCC-Ag were also still contro-
versial. Cyfra21-1 is a small molecular protein respon-
sible for structural integrity of epithelial cells, which also
Figure 1 Kaplan-Meier survival analysis in patients with stage II ESCC. (A) Overall survival curve for whole cohort of patients with stage II
ESCC; (B) Overall survival curve for whole cohort of patients with stage II ESCC according to the preoperative serum level of Cyfra21-1; (C) Overall
survival curve for whole cohort of patients with stage II ESCC according to the preoperative serum level of SCC-Ag; (D) Overall survival curve for
whole cohort of patients with stage II ESCC according to the preoperative serum level of Cyfra21-1 and SCC-Ag (double-normal subset vs.
either-normal subset vs. double-high subset).
Table 3 Prognostic value of preoperative Cyfra21-1 and SCC-Ag level in ESCC patients
Biomarker Cyfra21-1 SCC-Ag
Level No. Median OS 5-year survival P value* No. Median OS 5-year survival P value*
Total <0.001 <0.001
Low 198 91.9 85% 103 89.7 82%
High 181 46.6 33% 276 63.7 53%
pTNM stage
Stage IIA <0.001 0.069
Low 75 102.6 93% 46 85.7 86%
High 52 59.9 54% 81 78.2 72%
Stage IIB <0.001 <0.001
Low 123 84.4 80% 57 73.7 78%
High 129 41.1 25% 195 57.1 45%
Abbreviation: pTNM stage, pathological tumor-node-metastasis stage.
* Log-rank test.
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Table 4 Univariate and multivariate Cox regression analysis for overall survival in patients with ESCC
Univariate analysis Multivariate analysis
Characteristics HR 95% CI P value* HR 95% CI P value*
Age, years 1.014 1.001 to 1.028 0.038 0.998 0.985-1.012 0.764
Sex
Male vs. Female 1.212 0.902 to 1.629 0.202 - - -
Tumor location
Upper vs. Middle vs. Lower 0.980 0.558 to 1,611 0.318 - - -
Tumor Grade
Grade 1 vs. 2 vs. 3 1.668 1.085 to 2.166 0.056 - - -
pTNM stage
Stage IIA vs. Stage IIB 2.283 1.600 to 3.257 <0.001 2.191 1.533 to 3.132 <0.001
Cyfra21-1 level
Low vs. High 7.439 5.178 to 10.686 <0.001 7.149 4.961 to 10.303 <0.001
SCC-Ag level
Low vs. High 3.940 2.229 to 6.964 <0.001 2.926 1.655 to 5.175 <0.001
Abbreviation: HR, hazard ratio; 95% CI, 95% confidence interval; pTNM stage, pathological tumor-node-metastasis stage.
* Cox proportional hazards model.
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and invasion [34]. High Cyfra21-1 serum titers have
been demonstrated to correspond to poor prognosis in
patients with non small cell lung cancer and colorectal
cancer [21,26,33]. SCC-Ag may be involved in the malig-
nant behavior of squamous cell cancers, functioning in
invasion and/or metastasis. Associations between serum
SCC-Ag concentrations and patient survival have also
been observed [19,33,35,36]. In the current study, when
we focused exclusively on the survivals of patients, along
with the pTNM stage, the preoperative serum level of
Cyfra21-1 and SCC-Ag were shown to be independent
and significant prognostic parameter in surgically
resected stage II ESCCs (Table 4). Interestingly, in the
subset analyses, Cyfra21-1 and SCC-Ag level displayed
statistically significant effect on survival in stage IIB
patients. Furthermore, the present study indicated that
the double low subset, either-low subset and double-
high subset have significantly different survival
(P < 0.001, Figure 1D), suggesting that prognostic infor-
mation may be attainted from initial serum titers of
Cyfra21-1 and SCC-Ag.
Although this study has revealed the prognostic sig-
nificance of preoperative Cyfra21-1 and SCC-Ag serum
titers, we acknowledged that there were some limitations
in our study. Our study is a retrospective study, relied
exclusively on a single-institutional database. Additional
investigation into this area must be performed.
Conclusions
In conclusion, our findings identified that stage II ESCC
patients with poor prognoses are certainly predictable.
The high preoperative serum level of Cyfra21-1 andSCC-Ag are independently significant predictors which
negatively affected the survivals of patients with stage II
ESCC. A future confirmatory study or investigation for
patient-tailored adjuvant treatment with stratification
according to Cyfra21-1 and SCC-Ag serum level are
therefore warranted to evaluate whether such selection
may ultimately improve patient prognosis after surgery
for this deadly cancer.
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